HCM

HUTCHMED (China) Limited

18.77 USD

Last updated Nov 30, 05:31 UTC

Yesterday HIGH

$19.69

Yesterday LOW

$19.28

52w HIGH

$21.28

52w LOW

$10.68

EPS

0.97

PE

19.35

Next Earnings

Feb 27, 2024

Overview News Government Trades

HUTCHMED (China) Limited stock is down -3.64% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 87.5% of the previous 7 November’s closed higher than October. 50% of analysts rate it a buy.

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and gastric cancer (GC) In addition, it develops Tazemetostat, an inhibitors of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Hong Kong, Hong Kong

Website

hutch-med.com

Lisa Levin

Mon Aug 7, 2023

Sohu.com, Cloudflare And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.
Lisa Levin

Tue Aug 1, 2023

Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list.
Lisa Levin

Tue Aug 1, 2023

Caterpillar, Oshkosh, AudioCodes And Other Big Stocks Moving Higher On Tuesday

U.S. stocks traded lower, with the Nasdaq Composite falling around 70 points on Tuesday. Here are some big stocks recording gains in today’s session.
Benzinga Newsdesk

Mon Jul 31, 2023

HUTCHMED (China) H1 EPADS $0.97 Up From $(0.96) YoY, Sales $532.87M Up From $202.05M YoY

HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.97 per share. This is a 201.04 percent increase over losses of $(0.96) per share from the same period last year. The company reported $532.87 million in
Benzinga Insights

Mon Jul 31, 2023

Earnings Scheduled For July 31, 2023

Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million.
richadhand@benzinga.com

Mon Jul 24, 2023

Cantor Fitzgerald Reiterates Overweight on HUTCHMED (China), Maintains $50 Price Target

Cantor Fitzgerald analyst Louise Chen reiterates HUTCHMED (China) (NASDAQ:HCM) with a Overweight and maintains $50 price target.
Benzinga Newsdesk

Thu Jul 20, 2023

HUTCHMED Receives Breakthrough Therapy Designation In China For Fruquintinib Combination With Sintilimab

HUTCHMED announces that the Center for Drug Evaluation of China's National Medical Products Administration ("NMPA") has granted Breakthrough Therapy Designation ("BTD") to the combination of
Benzinga Newsdesk

Mon Jul 10, 2023

HUTCHMED Initiates Phase I Study Of Its Novel SHP2 Inhibitor HMPL-415 For Advanced Malignant Solid Tumors In China
Benzinga Insights

Tue Jun 20, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Newsdesk

Fri Jun 16, 2023

Hutchmed And Takeda Announced That Results Of Phase 3 FRESCO-2 Study Of Fruquintinib In Patients With Previously Treated Metastatic Colorectal Cancer Were Published In The Lancet, Showing That Fruquintinib Reduced The Risk Of Death By 34%

Deutsche Bank

Fri Nov 24, 04:59

buy

upgrade
Goldman Sachs

Fri Nov 10, 11:03

hold

confirm